The Cocktail Report (sound really smart around your friends):
In the NHS-Galleri trial of 142,250 people aged 50 to 77, adding the test did not reduce late-stage cancer diagnoses after three yearly rounds.
In the U.S. PATHFINDER 2 study of 35,878 adults, 60.3% of positive results turned out to be real cancers.
The same test caught only 39.3% of the cancers that showed up within a year.
An FDA advisory panel voted 10 to 0 that the test is safe, but only 6 to 4 that it works.
A negative result does not rule out cancer, and the test does not replace mammograms, colonoscopies, or lung scans.
If you are 50 or older, you may have seen ads for a blood test that screens for more than 50 cancers at once. This week produced the best evidence so far on whether that test, GRAIL's Galleri, earns a place in your checkup.
The answer is mixed, and the details matter more than the headlines.
Galleri reads cell-free DNA, which is the fragments of genetic material that cells shed into the blood. It looks for methylation patterns, chemical tags on DNA that differ between healthy and cancerous cells, and then predicts where in the body a cancer signal is coming from.
The big trial came up short:
NHS-Galleri randomized 142,250 people in England aged 50 to 77 to either usual care or usual care plus three annual Galleri tests. The goal was fewer cancers found at stage III or IV, the advanced stages that are hardest to treat.
That goal was not met:
After three rounds, stage III or IV diagnoses across 12 prespecified cancer types ran at 300.5 cases for every 100,000 people followed for a year in the test group and 292.5 in the usual-care group, a gap that was not statistically meaningful.
There were hints in the fine print. Stage IV cancers alone ran about 14% lower in the test group, and the second and third rounds looked better than the first, but the trial was not designed to prove those points.
The U.S. study measured accuracy, not survival:
PATHFINDER 2 gave the test once to 35,878 American and Canadian adults aged 50 and up with no suspicion of cancer. It had no comparison group.
Among 32,007 people with full follow-up, 0.54% had a cancer found by the test. Of those who got a positive result, 60.3% really had cancer, and the test guessed the right organ 91.3% of the time.
False alarms were rare: specificity, the share of cancer-free people correctly told they were clear, was 99.64%. Only 0.6% of participants went on to an invasive follow-up procedure after a positive result, and 90.5% of those were not surgery.
The weak spot is sensitivity, the share of real cancers the test catches. It flagged 39.3% of all cancers diagnosed within a year, rising to 69.8% for a prespecified group of 12 cancer types.
That means roughly six of every ten cancers were missed. In the U.K. trial the test caught between 26.7% and 37.2% of all cancers in each round.
What the FDA panel said:
On September 23, an FDA advisory committee voted 10 to 0 that Galleri is safe for adults 50 and older. The panel split 6 to 4 on whether it is effective and voted 7 to 2, with one abstention, that benefits outweigh risks.
The FDA does not have to follow its advisers. The proposed label itself says a negative result does not rule out cancer and that the test is not a substitute for standard screening.
The fine print on who paid:
GRAIL designed and funded PATHFINDER 2 and helped analyze and write it. The study also covered the cost of follow-up scans, so nobody yet knows how real-world bills would change what people do after a positive result.
Where this leaves you:
If you are weighing this test, treat it as an add-on with a real blind spot, not a clean bill of health. A positive result is worth taking seriously, since more than half turned out to be cancer.
A negative one should change nothing about your mammogram, colonoscopy, or lung scan schedule. The trial that would settle the question of whether the test helps people live longer has not been done.
Why Should You Care?
A test that finds some cancers early but misses most of them can still give false comfort, and false comfort is how people skip the screenings that are proven to save lives. Know what a negative result does not mean before you pay for one.
1. Nabavizadeh N, McDonnell C, Kurbegov D, et al. Performance and safety of a multi-cancer early detection test: the PATHFINDER 2 study. Nature Medicine. Published September 22, 2026. doi:10.1038/s41591-026-04618-w. https://www.nature.com/articles/s41591-026-04618-w
2. Neal RD, Dolly S, Johnson P, et al. Performance of a multi-cancer early detection test in the randomized controlled NHS-Galleri trial. Nature Medicine. Published September 22, 2026. doi:10.1038/s41591-026-04652-8. https://www.nature.com/articles/s41591-026-04652-8
3. Cortese T. FDA MCGP panel votes in favor of the Galleri multicancer early detection test. CancerNetwork. September 23, 2026. https://www.cancernetwork.com/view/fda-mcgp-panel-votes-in-favor-of-the-galleri-multicancer-early-detection-test
